Patton Albertson Miller Group LLC Has $681,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)

Patton Albertson Miller Group LLC cut its position in shares of Novo Nordisk A/S (NYSE:NVO) by 3.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,720 shares of the company’s stock after selling 180 shares during the period. Patton Albertson Miller Group LLC’s holdings in Novo Nordisk A/S were worth $681,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in NVO. Horizon Kinetics Asset Management LLC lifted its stake in Novo Nordisk A/S by 1.6% in the third quarter. Horizon Kinetics Asset Management LLC now owns 15,718 shares of the company’s stock valued at $1,872,000 after acquiring an additional 250 shares during the last quarter. Hancock Whitney Corp boosted its holdings in Novo Nordisk A/S by 5.0% in the third quarter. Hancock Whitney Corp now owns 6,273 shares of the company’s stock worth $747,000 after purchasing an additional 300 shares in the last quarter. Brown Brothers Harriman & Co. increased its position in Novo Nordisk A/S by 4.7% during the third quarter. Brown Brothers Harriman & Co. now owns 37,367 shares of the company’s stock worth $4,449,000 after buying an additional 1,688 shares during the last quarter. Boston Family Office LLC raised its holdings in Novo Nordisk A/S by 3.0% during the third quarter. Boston Family Office LLC now owns 44,524 shares of the company’s stock valued at $5,301,000 after buying an additional 1,280 shares in the last quarter. Finally, Independent Advisor Alliance lifted its position in shares of Novo Nordisk A/S by 2.0% in the third quarter. Independent Advisor Alliance now owns 71,534 shares of the company’s stock worth $8,518,000 after buying an additional 1,385 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $104.56 on Tuesday. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15. The company has a market cap of $469.22 billion, a P/E ratio of 33.84, a P/E/G ratio of 1.35 and a beta of 0.42. The business’s 50 day moving average is $114.83 and its two-hundred day moving average is $128.64. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.